Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) has received a consensus rating of “Buy” from the six research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $17.82.
A number of research firms have weighed in on ELEV. Wedbush lowered their price target on Elevation Oncology from $27.00 to $21.00 and set an “outperform” rating on the stock in a research report on Friday, March 4th. Zacks Investment Research upgraded Elevation Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, March 8th.
Shares of ELEV stock opened at $2.44 on Wednesday. Elevation Oncology has a 52-week low of $2.28 and a 52-week high of $16.22. The business’s fifty day moving average is $2.85 and its 200 day moving average is $5.01.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC grew its stake in shares of Elevation Oncology by 18.3% in the third quarter. Janus Henderson Group PLC now owns 1,220,205 shares of the company’s stock worth $9,380,000 after purchasing an additional 188,517 shares during the last quarter. TCG Crossover Management LLC bought a new stake in Elevation Oncology during the 4th quarter valued at approximately $3,341,000. Sio Capital Management LLC bought a new stake in Elevation Oncology during the 4th quarter valued at approximately $1,505,000. Caxton Corp boosted its position in Elevation Oncology by 21.7% during the 3rd quarter. Caxton Corp now owns 48,183 shares of the company’s stock valued at $375,000 after acquiring an additional 8,597 shares in the last quarter. Finally, Marquette Asset Management LLC boosted its position in Elevation Oncology by 332.5% during the 1st quarter. Marquette Asset Management LLC now owns 38,951 shares of the company’s stock valued at $98,000 after acquiring an additional 29,945 shares in the last quarter. 78.42% of the stock is currently owned by institutional investors.
About Elevation Oncology (Get Rating)
Elevation Oncology, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion.
- Get a free copy of the StockNews.com research report on Elevation Oncology (ELEV)
- Las Vegas Sands Stock Could be a Winning Bet Down Here
- Newmont Corporation is the Same as It’s Always Been Which is Why It’s a Buy
- Simpson Manufacturing Co. Hits The Nail On The Head, Again
- The Sherwin-Williams Company Bottoms Above Institutional Support
- What To Make Of Activision Blizzard (NASDAQ: ATVI)
Receive News & Ratings for Elevation Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevation Oncology and related companies with MarketBeat.com's FREE daily email newsletter.